Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors
Galsky M, Camacho L, Chiorean E, Mulkerin D, Hong D, Oh W, Bajorin D. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. Annals Of Oncology 2011, 23: 1037-1044. PMID: 21828377, DOI: 10.1093/annonc/mdr358.Peer-Reviewed Original ResearchConceptsRenal impairmentRenal functionSolid tumorsModerate to severe renal impairmentDay 1Dose-limiting toxic effectsEffect of renal impairmentDegree of renal impairmentRefractory to standard therapyLevel of renal functionRenal function groupMild renal impairmentRefractory solid tumorsSevere renal impairmentNormal renal functionPhase I studyCohort of patientsDose deescalationPlasma platinumStandard therapyToxic effectsUltrafiltrable platinumAdverse eventsPlatinum analogsGroup 1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply